Suppr超能文献

1,3-二丙基-8-环戊基黄嘌呤(CPX)的物理特性描述。

Physical Characterization of 1,3-dipropyl-8-cyclopentylxanthine (CPX).

机构信息

Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville School of Pharmacy, Edwardsville, Illinois 62026, USA.

出版信息

AAPS PharmSciTech. 2010 Jun;11(2):720-8. doi: 10.1208/s12249-010-9436-6. Epub 2010 May 4.

Abstract

1,3-dipropyl-8-cyclopentylxanthine (CPX) has been shown to stimulate in vitro CFTR activity in F508 cells. Data from a phase I study demonstrated erratic bioavailability and no measurable clinical response to oral CPX. One cause for its poor bioavailability may have been dissolution rate limited absorption, but there is little published physicochemical data on which to base an analysis. The objective of this study was to determine the solubility and solid-state characteristics of CPX. CPX is a weak acid with pKa of 9.83 and water solubility at pH 7.0 of 15.6 microM. Both laureth-23 and poloxamer 407 increased the apparent water solubility linearly with increasing concentrations. CPX exists in two crystal forms, one of which (form II) has been solved. Form II is a triclinic crystal with space group P1 and calculated density of 1.278 g/cm(3). X-ray powder diffraction and differential scanning calorimetry studies (DSC) indicated that CPX crystals prepared at room temperature were mixtures of forms I and II. DSC results indicated a melting point of approximately 195 degrees C for form I and 198 degrees C for form II. Thermogravimetric analysis indicated no solvent loss upon heating. Dynamic water vapor sorption data indicated no significant water uptake by CPX up to 90% RH. Analysis of the data indicates that CPX may not be amenable to traditional formulation approaches for oral delivery.

摘要

1,3-二丙基-8-环戊基黄嘌呤(CPX)已被证明可在 F508 细胞中刺激体外 CFTR 活性。I 期研究数据表明,CPX 的生物利用度不稳定,口服 CPX 无明显临床反应。其生物利用度差的一个原因可能是溶解速率限制了吸收,但关于这方面的分析很少有发表的物理化学数据。本研究的目的是确定 CPX 的溶解度和固态特性。CPX 是一种弱酸,pKa 为 9.83,在 pH7.0 时的水溶解度为 15.6μM。月桂醇醚-23 和泊洛沙姆 407 均使 CPX 的表观水溶解度随浓度的增加呈线性增加。CPX 存在两种晶体形式,其中一种(形式 II)已被解析。形式 II 是一种具有 P1 空间群的三斜晶系晶体,计算密度为 1.278g/cm(3)。X 射线粉末衍射和差示扫描量热法(DSC)研究表明,在室温下制备的 CPX 晶体是形式 I 和 II 的混合物。DSC 结果表明形式 I 的熔点约为 195°C,形式 II 的熔点约为 198°C。热重分析表明加热时没有溶剂损失。动态水蒸气吸附数据表明 CPX 在 90%RH 下没有明显的吸水量。数据分析表明,CPX 可能不适合传统的口服制剂方法。

相似文献

本文引用的文献

10
A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis.
Pediatr Pulmonol. 2002 Feb;33(2):90-8. doi: 10.1002/ppul.10041.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验